Description:
Bromodeoxyuridine (BrdU) is a thymidine analog and is specifically incorporated into DNA during DNA synthesis. Anti-bromodeoxyuridine monoclonal antibody is used to identify cells that have incorporated BrdU. This immunological detection scheme has several advantages over the use of radioactive thymidine incorporation for identifying cells under-going replication. Labeling and detection can be performed the same day instead of waiting several days, as required for autoradiography of tritium-labeled cells, and the necessity of using multiple specimens for obtaining the optimal exposure time is eliminated. In addition, anti-bromodeoxyuridine staining with flow cytometric analysis allows multiple parameters to be evaluated simultaneously.
Applications: Immunocytochemistry Flow Cytometry
|
| Type | Isotype | Clone | Grade |
|---|
| Mab | IgG | 2Q2298 | Supernatant |
|
| Size | | Storage | Shipping | Source | Host |
|---|
| 100ul | | -20°C | Blue Ice | | Mouse |
|
| Concentration: |
| As reported |
| Immunogen: |
| Bromodeoxyuridine |
| Purity: |
| Culture supernatant. |
| Form |
| Liquid. Contains no preservative. |
| Specificity: |
| Binds to bromodeoxyuridine and crossreacts with iodouridine (10%). Does not crossreact with fluorodeoxyuridine, nor with any endogenous cellular components such as thymidine or uridine. |
|
| Intended for research use only. Not for use in human, therapeutic, or diagnostic applications. |
Gonchoroff, NJ et al. A monoclonal antibody reactive with 5-Bromo-2- deoxyuridine that does not require DNA denaturation. Cytometry. 6:506–512, 1985. Greipp, PR et al. Immunofluorescent plasma cell labeling indices (LI) using a monoclonal antibody (BU-1). Am. J. Hematol. 20:289–292, 1985. Gonchoroff, NJ et al. S-phase detection with an antibody to bromodeoxyuridine. Role of Dnase pretreatment. J. Immunol. Methods. 97:97- 101, 1986. Greipp, PR et al. Immunofluorescent labeling indices in myeloma and related monoclonal gammopathies. Mayo Clin Proc. 62:969–977, 1987.
|
|
